← Leaderboards
Taolin Yi
Cleveland Clinic Foundation
$3,372,347
Attributed
$3,372,347
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $611.8K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$3,372,347 · 4
By mechanism
R01$3,372,347 · 4
Top collaborators
No co-investigators on record.
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- Ernest C. Borden$3,599,637
- Daniel J Lindner$2,056,260
Others in their field
Top investigators on “Protein Tyrosine Phosphatase”
- Nicholas K Tonks · Cold Spring Harbor Laboratory$25,899,340
- Nunzio Bottini · University Of Southern California$17,835,887
- Benjamin G. Neel · New York University School Of Medicine$15,765,169
- Zhong-Yin Zhang · Purdue University$15,238,248
- Gen-Sheng Feng · University Of California, San Diego$14,257,616
- Tony R. Hunter · Salk Institute For Biological Studies$12,894,505
Research focus
Protein Tyrosine PhosphataseBiological Signal TransductionTissue /Cell CultureCell Growth RegulationMass SpectrometryAthymic MouseCell LinePhosphorylationPolymerase Chain ReactionTranscription FactorProtein LocalizationAntineoplasticsActive SitesPhosphatase InhibitorMolecular CloningProtein SequenceEnzyme MechanismNatural Killer CellsConfocal Scanning MicroscopyCell NucleusImmunofluorescence TechniqueEnzyme ActivityProtein BindingNeoplasm /Cancer Therapy
Grant awards (14)
Anti-Cancer Activities of PTPase Inhibitors$321,891
R01 · FY2007 · CA · contact PI
Anti-Cancer Activities of PTPase Inhibitors$331,504
R01 · FY2006 · CA · contact PI
Anti-Cancer Activities of PTPase Inhibitors$339,482
R01 · FY2005 · CA
PTPases as Therapeutic Targets$272,340
R01 · FY2005 · CA
Anti-Cancer Activities of PTPase Inhibitors$339,482
R01 · FY2004 · CA
PTPases as Therapeutic Targets$272,340
R01 · FY2004 · CA
Anti-Cancer Activities of PTPase Inhibitors$327,269
R01 · FY2003 · CA
PTPases as Therapeutic Targets$272,340
R01 · FY2003 · CA
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY$163,224
R01 · FY2003 · GM
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY$158,529
R01 · FY2002 · GM
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY$153,970
R01 · FY2001 · GM
SHP-1/TYK2 INTERACTION AND ITS DEFECT IN FHLH DISEASE$137,189
R01 · FY2001 · CA
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY$149,543
R01 · FY2000 · GM
SHP-1/TYK2 INTERACTION AND ITS DEFECT IN FHLH DISEASE$133,244
R01 · FY2000 · CA